NCT07637734
Cantharidin Application in Patients With Common Warts (Verruca Vulgaris) (COVE-3)
Not Yet Recruiting
PHASE3Ages 2+InterventionalTreatmentVerrica Pharmaceuticals Inc.
~300 participants
Updated 2026-06-10 on ClinicalTrials.gov
What's tested:VP-102 (US) / TO-208 (Japan)Vehicle (US) / Vehicle (Japan)
At a glance
Recruiting sites
0 of 2 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Proportion of subjects achieving complete clearance of all treatable common warts (baseline and new) at the Day 84 (EOT) Visit.
Measured over Day 84 (0/+8 days)
Conditions
Where it's being run
2 sites across 2 statesKansas1
Louisiana1
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Proportion of subjects achieving complete clearance of all treatable common warts (baseline and new) at the Day 84 (EOT) Visit.Day 84 (0/+8 days)
To evaluate the efficacy of YCANTH (VP-102/TO-208) relative to Vehicle by assessing the proportion of subjects achieving complete clearance defined by complete resolution of all common warts as assessed visually by a Blinded Assessor of all treatable common warts, at the EOT Visit (Day 84).